Dr. Douglas M. Carnes '64
Bachelor of Science degree, Pre-Medicine, The Citadel, Charleston, SC; Masters in Science Education, University of Georgia, Doctorate in Microbiology and Biochemistry, University of Georgia.
Dr. Carnes began his medical education career working in the pharmaceutical industry for SmithKline and French (SK&F), Laboratories in 1973. Doug began his tenure with SK&F as Regional Medical Liaison for the Southwest region of the country. During that time, he worked directly with 20 major medical teaching centers, public and private hospitals, and Federal, State and Local hospitals systems helping to improve patient care and infection control.
Doug became a District Sales Manager in 1976 for the Southeast Sale Region and was based in Raleigh, NC. In January of 1976, Dr. Carnes was brought into the home office to develop, coordinate and oversee the introduction of the world’s first H2 antagonist blocker – Tagamet. Doug headed the company’s training departments where he was responsible for all sales representative and manager training. While at SK&F, Doug ran the quality control and distribution operations for the corporation.
Doug left the large corporate environment in the mid 1980’s to become an entrepreneur in the field of medical education, marketing and communications forming Carnes Communications, Inc... Doug’s company grew from a modest seven person, one-half million corporation to a large one hundred and twenty-five person, twenty million dollar company when it was sold in January of 1998. The corporation serviced the pharmaceutical industry developing and delivering educational programs to sales representatives, and health care professionals. The company worked in video, film, print, live and internet media. Doug has been recognized by several medical professional societies for the quality and timeliness of his company’s medical educational programming.
When the company was sold to HealthAnswers, Inc. in 1998, Doug became Corporate Executive Vice President of marketing and strategic business development. Prior to his retirement Doug developed and implemented the company’s strategic entry into the internet health care market arena. Since his retirement, Doug has continued to serve as a consultant to the medical communications industry.
From 2002 - 2014, Doug served as an Adjunct Professor in the Department of Business Administration, teaching Strategic Management and Entrepreneurship. In 2012 Doug became CEO of ImmunoLogix, Inc. a Charleston based biopharmaceutical company. ImmunoLogix, Inc. held exclusive patent and proprietary rights to the only technology making 100% human antibodies from human tonsils. In 2013 Doug negotiated the sale of ImmunoLogix, Inc. to Intrexon corporation located in Reston, Va. Doug now serves as CEO of Kerdea Technologies a technology development company servicing the automobile engine management market.